علاج ورم ديسمويد في الأمعاء الدقيقة عند فشل المراقبة النشطة

References

DOI: 10.1002/cncr.34332

• Current options for medical management include tyrosine kinase inhibitors as well as more conventional cytotoxic chemotherapy (e.g., anthracycline-based or methotrexate-based regimens).
• Of note, unlike cytotoxic chemotherapy, in which treatment cycles are limited, TKIs are generally used continuously until intolerance develops or disease progresses.
• Typically, low-dose methotrexate plus vinblastine or vinorelbine, or, alternatively, a conventional anthracycline-containing regimen is associated with disease control rates (DCRs) of 64%–100%.
• Among the patients who were evaluable for pain, 74% had symptomatic improvement after 3 months.